US2008096263A1PendingUtilityA1

Recombinant Parainfluenza Virus Expression Systems And Vaccines Comprising Heterologous Antigens Derived From Respiratory Syncytial Virus

Assignee: MEDIMMUNE INCPriority: Feb 21, 2002Filed: Jun 14, 2007Published: Apr 24, 2008
Est. expiryFeb 21, 2022(expired)· nominal 20-yr term from priority
A61P 35/02A61P 31/16A61P 37/04A61P 37/00A61P 37/02A61P 31/12A61P 31/14A61P 7/00A61P 35/00A61P 13/12A61P 11/00A61P 19/00A61P 11/06C07K 16/11C12N 2710/22034C12N 2840/203C12N 2760/18621C12N 2760/18634G01N 33/502A61K 39/155C07K 14/005C12N 2760/18534G01N 33/56983C12N 2760/18522A61K 39/12A61K 2039/58C12N 2760/18643C12N 15/86A61K 2039/545G01N 33/5011C12N 2760/18334A61K 2039/5254C12Q 2600/158C12N 2760/18343C12N 2760/18622A61K 2039/5256C12N 2760/18321C12N 7/00G01N 33/5088G01N 33/5008A61K 2123/00C12N 2760/18322A61K 2039/552A61K 2039/70C12Q 1/701G01N 2333/08A61K 39/00Y02A90/10
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

Claims

exact text as granted — not AI-modified
1 - 48 . (canceled)  
     
     
         49 . A recombinant parainfluenza virus (PIV) comprising: 
 a recombinant bovine PIV type 3 (bPIV3) genome, wherein the bPIV3 genome comprises: 
 bPIV3 nucleotide sequences encoding nucleoprotein (N), phosphoprotein (P), matrix (M), and large protein (L) proteins;  
 human PIV type 3 (hPIV3) nucleotide sequences encoding fusion (F) and hemagglutinin-neuraminidase glycoprotein (HN) proteins, wherein the nucleotide sequences encoding the hPIV3 F and HN proteins substitute for nucleotide sequences encoding bPIV3 F and HN proteins; and  
 a nucleic acid sequence encoding a respiratory syncytial virus (RSV) F protein, wherein the nucleic acid sequence encoding the RSV F protein is inserted at nucleotide position 104 or 1774 of the bPIV3 genome.  
   
     
     
         50 . The recombinant PIV of  claim 49  wherein the nucleic acid sequence encoding the RSV F protein is inserted at nucleotide position 1774 of the bPIV3 genome.  
     
     
         51 . The recombinant PIV of  claim 49  wherein the hPIV3 is hPIV3/Tex/12084/1983.  
     
     
         52 . The recombinant PIV of  claim 50  wherein the hPIV is hPIV3/Tex/12084/1983.  
     
     
         53 . The recombinant PIV of  claim 49  wherein the bPIV3 is Kansas-strain bPIV3.  
     
     
         54 . The recombinant PIV of  claim 50  wherein the bPIV3 is Kansas strain bPIV3.  
     
     
         55 . The recombinant PIV of  claim 52  wherein the bPIV3 is Kansas-strain bPIV3.  
     
     
         56 . The recombinant PIV of  claim 49  wherein the RSV F protein comprises the amino acid sequence shown in SEQ ID NO:7.  
     
     
         57 . The recombinant PIV of  claim 50  wherein the RSV F protein comprises the amino acid sequence shown in SEQ ID NO:7.  
     
     
         58 . The recombinant PIV of  claim 52  wherein the RSV F protein comprises the amino acid sequence shown in SEQ ID NO:7.  
     
     
         59 . The recombinant PIV of  claim 54  wherein the RSV F protein comprises the amino acid sequence shown in SEQ ID NO:7.  
     
     
         60 . The recombinant PIV of  claim 55  wherein the RSV F protein comprises the amino acid sequence shown in SEQ ID NO:7.  
     
     
         61 . The recombinant PIV of  claim 49  wherein the nucleic acid sequence encoding the RSV F protein is inserted at nucleotide position 104 of the bPIV3 genome.  
     
     
         62 . The recombinant PIV of  claim 61  wherein the hPIV is hPIV3/Tex/12084/1983.  
     
     
         63 . The recombinant PIV of  claim 61  wherein the bPIV3 is Kansas strain bPIV3.  
     
     
         64 . The recombinant PIV of  claim 62  wherein the bPIV3 is Kansas-strain bPIV3.  
     
     
         65 . The recombinant PIV of  claim 61  wherein the RSV F protein comprises the amino acid sequence shown in SEQ ID NO:7.  
     
     
         66 . The recombinant PIV of  claim 62  wherein the RSV F protein comprises the amino acid sequence shown in SEQ ID NO:7.  
     
     
         67 . The recombinant PIV of  claim 63  wherein the RSV F protein comprises the amino acid sequence shown in SEQ ID NO:7.  
     
     
         68 . The recombinant PIV of  claim 64  wherein the RSV F protein comprises the amino acid sequence shown in SEQ ID NO:7.

Join the waitlist — get patent alerts

Track US2008096263A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.